ArticleJournal of neurology, neurosurgery, and psychiatry2017
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
Article in Journal of neurology, neurosurgery, and psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 6 syntheses or guidelines pooled it, 257 citations in OpenAlex.
- Suicide Ideation, Attempts, and Mortality in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
- Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.Journal of neurology · 2024Pooled it
- Sleep and cognitive outcomes in multiple sclerosis; a systematic review.BMC psychiatry · 2024Pooled it
- Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Systematic Review of the Socioeconomic Consequences in Patients With Multiple Sclerosis With Different Levels of Disability and Cognitive Function.Frontiers in neurology · 2021Pooled it
- EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis.Journal of palliative medicine · 2020Guideline
- Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.Annals of neurology · 2025Trial
- Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.Advances in therapy · 2025Trial
- Advance care planning in multiple sclerosis (ConCure-SM): A multicenter single-arm pilot and feasibility study.PloS one · 2025Trial
- Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.Journal of neurology · 2024Trial
- Trial
- Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.Neurology and therapy · 2026Article
- Complex intervention for MS patients in Germany - can it be cost-saving for the society?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).Neurology · 2026Article
- Can Multiple Sclerosis be Managed Over a Lifetime? A Rare 72-Year Journey of Pediatric-Onset to Secondary Progressive Multiple Sclerosis.Clinical case reports · 2026Article
- Aging with multiple sclerosis and associated prevalence, incidence, comorbidities and healthcare utilization patterns in a population based study.Scientific reports · 2026Article
- Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.Neurology and therapy · 2026Review
- Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Unexpected longevity in myasthenia gravis: a multi-state population-based comparison with multiple sclerosis and the U.S. population.Therapeutic advances in neurological disorders · 2026Article
- Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT).British journal of haematology · 2025Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSurvival and causes of death (COD) in multiple sclerosis (MS) provide ultimate endpoints. We aimed to investigate survival and COD in a 60-year population-based MS cohort compared with the general population.
methodsAll patients with incident multiple sclerosis (MS) (N=1388) with onset during 1953-2012 in Hordaland County, Western Norway, were included. Data were obtained from patient records at Haukeland University Hospital and linked to the Norwegian COD registry. Survival adjusted for sex, age and disease course were estimated by Kaplan-Meier analyses from birth and from disease onset. Mortality and COD in MS relative to the general population were examined by standardised mortality ratio (SMR).
resultsOf 1388 patients, 291 had deceased, mainly of MS (56.4%). Median life expectancy was 74.7 years for MS and 81.8 years for the general population (p<0.001); 77.2 years for women with MS and 72.2 years for men with MS (p<0.001). Life expectancy for patients with relapsing remitting MS (RRMS) was 77.8 years and -71.4 years for primary progressive MS (PPMS) (p<0.001). Overall SMR was 2.7 (p>0.0001); 2.9 in women and 2.5 in men (p=0.0009). SMR was 2.4 in RRMS and 3.9 in PPMS (p<0.0001). SMR from disease onset during 1953-1974 was 3.1; 2.6 during 1975-1996 and 0.7 during 1997-2012 (p<0.0083). No difference in cause-specific deaths were found (p=0.0871).
conclusionWe found a 7-year shorter life expectancy and almost threefold higher mortality in MS compared with the general population. A rise in survival in MS was observed during the entire observation period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.